Results 131 to 140 of about 8,187 (238)

An immune-mediated effect of the antibiotic cefiderocol on LPS-induced acute lung injury

open access: yesAntimicrobial Agents and Chemotherapy
This study examines the immune-modulatory effects of cefiderocol in a murine model of lipopolysaccharide (LPS)-induced acute lung injury (ALI). Cefiderocol pretreatment significantly reduced lung tissue damage, lowered pro-inflammatory cytokines, and ...
Min Hao   +4 more
doaj   +1 more source

Spontaneous Emergence of Cefiderocol Resistance in Klebsiella pneumoniae KPC-163: Genomic and Transcriptomic Insights

open access: yesAntibiotics
Background/Objectives: Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an urgent public health threat due to its rapid dissemination and resistance to last-line antibiotics.
Irene Luu   +13 more
semanticscholar   +1 more source

Multidrug-resistant Gram-negative clinical isolates with reduced susceptibility/resistance to cefiderocol : which are the best present and future therapeutic alternatives ?

open access: yes
Purpose: To evaluate the different present and future therapeutic β-lactam/β-lactamase inhibitor (BL/BLI) alternatives, namely aztreonam-avibactam, imipenem-relebactam, meropenem-vaborbactam, cefepime-zidebactam, cefepime-taniborbactam, meropenem ...
Le Terrier, Christophe   +3 more
core   +1 more source

Feasibility of 24 h continuous-infusion cefiderocol administered by elastomeric pump in attaining an aggressive PK/PD target in the treatment of NDM-producing Klebsiella pneumoniae otomastoiditis

open access: yesJAC-Antimicrobial Resistance
Objectives Cefiderocol has emerged as a key treatment for managing MDR infections, and its time-dependent pharmacodynamics are optimized by prolonged infusion to maintain time above the MIC (T > MIC).
Stella Babich   +5 more
semanticscholar   +1 more source

Treatment of Carbapenem-Resistant Acinetobacter baumannii in Real Life (T-ACI): A Prospective Single-Center Observational Study

open access: yesAntibiotics
Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) poses significant challenges in healthcare due to its multidrug resistance and high mortality rates among critically ill patients. Results: We enrolled 45 patients.
Antonio Riccardo Buonomo   +11 more
doaj   +1 more source

Activity of cefiderocol and innovative β-lactam/β-lactamase inhibitor combinations against isogenic strains of Escherichia coli expressing single and double β-lactamases under high and low permeability conditions.

open access: yesInternational Journal of Antimicrobial Agents
OBJECTIVES To analyze the impact of the most clinically relevant β-lactamases and their interplay with low outer membrane permeability on the activity of cefiderocol, ceftazidime/avibactam, aztreonam/avibactam, cefepime/enmetazobactam, cefepime ...
T. Blanco-Martín   +14 more
semanticscholar   +1 more source

Use of Cefiderocol in Adult Patients: Descriptive Analysis from a Prospective, Multicenter, Cohort Study

open access: yesInfectious Diseases and Therapy
Introduction Cefiderocol is a siderophore cephalosporin showing activity against various carbapenem-resistant Gram-negative bacteria (CR-GNB). No data currently exist about real-world use of cefiderocol in terms of types of therapy (e.g., empirical or ...
Daniele Roberto Giacobbe   +52 more
doaj   +1 more source

Interpretive agreement of susceptibility between broth microdilution and disk diffusion methods for cefiderocol, using criteria from the Clinical and Laboratory Standards Institute, European Committee on Antimicrobial Susceptibility Testing, and the Food and Drug Administration

open access: yesJournal of Clinical Microbiology
Cefiderocol (FDC) is a siderophore cephalosporin approved for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (MDR-GNB), including carbapenem-resistant (CR) isolates.
Yu-Tzu Lin   +5 more
semanticscholar   +1 more source

Cefiderocol in Difficult-to-Treat Nf-GNB in ICU Settings

open access: yes
Background The efficacy and safety of cefiderocol in ICU patients with difficult-to-treat resistance (DTR) non-fermenting Gram-negative bacteria (Nf-GNB) are not as well-established.
Jean Christophe Richard   +23 more
core   +1 more source

Commercially available tests for determining cefiderocol susceptibility display variable performance in the Achromobacter genus

open access: yes
International audienceBackground : Cefiderocol is a siderophore-conjugated cephalosporin increasingly used in the management of Achromobacter infections. Testing for cefiderocol susceptibility is challenging with distinct recommendations depending on the
Sorlin, Pauline   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy